Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Free Cash Flow: 2010-2025

Historic Free Cash Flow for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Sep 2025 value amounting to $47.6 million.

  • Ironwood Pharmaceuticals' Free Cash Flow rose 382.13% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.6 million, marking a year-over-year decrease of 45.36%. This contributed to the annual value of $103.4 million for FY2024, which is 43.54% down from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Free Cash Flow of $47.6 million as of Q3 2025, which was up 415.73% from -$15.1 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Free Cash Flow ranged from a high of $80.2 million in Q1 2023 and a low of -$15.1 million during Q2 2025.
  • Its 3-year average for Free Cash Flow is $30.8 million, with a median of $33.4 million in 2024.
  • Data for Ironwood Pharmaceuticals' Free Cash Flow shows a peak YoY increase of 382.13% (in 2025) and a maximum YoY decrease of 145.11% (in 2025) over the last 5 years.
  • Ironwood Pharmaceuticals' Free Cash Flow (Quarterly) stood at $64.4 million in 2021, then increased by 22.92% to $79.2 million in 2022, then tumbled by 55.03% to $35.6 million in 2023, then slumped by 57.29% to $15.2 million in 2024, then surged by 382.13% to $47.6 million in 2025.
  • Its Free Cash Flow was $47.6 million in Q3 2025, compared to -$15.1 million in Q2 2025 and $19.9 million in Q1 2025.